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We find that CD11c cells with many markers of dendritic cells
(DCs) are a major cell type in the skin lesions of psoriasis. These
CD11c cells, which are evident in both epidermis and dermis, are
the sites for the expression of two mediators of inflammation,
inducible nitric oxide synthase (iNOS) and TNF- in diseased skin.
These cells express HLA-DR, CD40, and CD86, lack the Langerin and
CD14 markers of Langerhans cells and monocytes, respectively, and
to a significant extent express the DC maturation markers DC-
LAMP and CD83. Treatment of psoriasis with efalizumab (anti-
CD11a, Raptiva) strongly reduces infiltration by these DCs in
patients responding to this agent. Disease activity after therapy
was more related to DC infiltrates and iNOS mRNA levels than T cell
infiltrates, and CD11c cells responded more quickly to therapy
than epidermal keratinocytes. Our results suggest that a type of
DC, which resembles murine ‘‘Tip-DCs’’ that can accumulate during
infection, has proinflammatory effects in psoriasis through nitric
oxide and TNF- production, and can be an important target for
suppressive therapies.
autoimmune disease  CD11c  Tip-DC
The common skin disease psoriasis serves as an accessible,model type 1 autoimmune disease (1–3). Evidence for this
view includes (i) a marked increase in the number of T cells in
diseased skin, (ii) the differentiation characteristics of these T
cells, including a skin-homing memory phenotype, a T helper
1Tc1 predominance, and oligoclonality, and (iii) the disease
improvements brought about by a variety of T cell-targeted
immunosuppressive agents (4–6). T cell functions are often
controlled by dendritic cells (DCs), and interestingly, psoriasis is
characterized by the production of IL-23 by CD11c DCs in
lesional skin (7). IL-23 is known to be a pivotal cytokine for
inflammation during experimental autoimmune encephalomy-
elitis in mice (8, 9).
To study the contribution and source of inflammatory mole-
cules in the pathogenesis of psoriasis (2), we have engaged in
detailed studies of disease resolution induced by specific biologic
antagonists. We have emphasized inflammatory mediators as-
sociated with CD11c cells, where high-level expression of this
integrin is a marker for many types of DCs (10, 11). We now
report that CD11c cells lacking the monocyte marker CD14 are
greatly increased in the dermis and epidermis of psoriasis
lesions, such that CD11c cells exceed T cells. Two critical
mediators of inflammation, TNF and inducible nitric oxide
synthase (iNOS), are simultaneously and primarily found in
these CD11c cells, which express HLA-DR, CD40 CD86, and
to some extent, DC maturation markers DC-LAMP and CD83.
Successful treatment of psoriasis with efalizumab (5), which
targets CD11a on leukocytes, strongly reduces infiltration by
these inflammatory DCs, which are similar to a cell type recently
described in the mouse: the TNF- and iNOS-producing DC or
‘‘Tip-DC’’ (12–14). Given recent evidence that TNF inhibitors
are able to reverse disease activity in psoriasis (15, 16), our data
suggest that Tip-DCs are a major inflammatory and effector cell
in psoriasis.
Materials and Methods
Skin Samples. Psoriasis lesions, nonlesional skin, and normal skin
were obtained from patients and normal volunteers under an
approved protocol (The Rockefeller University). Experiments
were conducted on samples obtained from a previously pub-
lished placebo-controlled clinical trial with efalizumab (n  65)
(Genentech and Xoma) (5). Patients treated with efalizumab
showed greater clinical improvement and reduction of epidermal
hyperplasia in skin lesions compared to placebo treatment. We
consider that thin epidermis without keratin 16 (K16) expression
represents histopathologic remission of psoriasis. None of the
patients in the placebo group were K16 at day 56, whereas 29
patients (37%) in the treatment arm were K16 at the end of the
study. Samples from other clinical trials with efalizumab (weekly
1 mgkg s.c. for 12 weeks) were used to measure iNOS mRNA
(n  13, see Fig. 4B), and a time-course of CD11c cell counts
(n  18, see Fig. 4D).
Antibodies. For immunohistochemistry, we used mouse anti-
human monoclonal antibodies to K16 (Sigma), CD3 (Becton
Dickinson), CD8 (BD PharMingen), CD83 (Becton Dickinson),
CD1a (Becton Dickinson), CD11c (BD PharMingen), iNOS (R
& D Systems) and CD14 (BD PharMingen). For immunofluo-
rescence, we localized CD11c (BD PharMingen), DC-LAMP
(Immunotech, Westbrook, ME), CD83 (Immunotech) (1:50–
1:100) with appropriate IgG goat anti-mouse Ig conjugated to
Alexa Fluor 488 or 546 (1:250) (Molecular Probes). The second
primary antibodies for two-color labeling were conjugated to the
fluorochrome or labeled by using the appropriate labeling kit
(Molecular Probes) (1:100–1:500): iNOS (R & D Systems) Alexa
Fluor 546, TNF- FITC (Becton Dickinson), HLA-DR FITC
(Becton Dickinson), HLA-DR phycoerythrin (PE) (Becton
Dickinson), Langerin (Immunotech) Alexa Fluor 488. The TNF
signal was amplified with a second secondary goat anti-FITC
antibody (Molecular Probes) for 30 min at 1 gml. Antibodies
for FACS include the following: mouse IgG1 FITC (Becton
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Dickinson), mouse IgG1 PE (Becton Dickinson), mouse IgG1
peridinin-chlorophyll-protein (PerCP) (Becton Dickinson),
HLA-DR allophycocyanin (Becton Dickinson), CD3 PerCP
(Becton Dickinson), CD83 FITC (Immunotech), CD86 FITC
(BD PharMingen), CD40 FITC (BD PharMingen), CD14 FITC
(Becton Dickinson), and CD11c PE (Becton Dickinson).
Tissue Sections. Skin biopsies were frozen in optimal cutting
temperature compound (Sakura Finetek, Tokyo), stored at
80°C, stained with hematoxylin (Fisher Scientific, Fair Lawn,
NJ) and eosin (Shandon, Pittsburgh), or with mouse anti-human
monoclonal antibodies as above using a published technique
(17). Data for epidermal thickness and K16 staining are taken
from all patients, whereas the rest of the antibodies in the panel
(CD1a, CD11c, CD83, CD3, and CD8) were applied to 42
subjects in the active drug group and 26 subjects in the placebo
group because of a limited number of tissue sections. For
immunofluorescence, frozen lesional tissue sections from pso-
riasis patients (n  8) were fixed in acetone and treated with 10%
normal horse serum. Primary antibodies were incubated over-
night at 4°C, the secondary antibody for 30 min, and the second
primary antibody for 2 h. Images were acquired by using
appropriate filters of a Zeiss Axioplan 2I microscope with Plan
Apochromat 20  0.7 numerical aperture lens and a Hagamatsu
orca ER-cooled charge-coupled device camera, controlled by
METAVUE software (Universal Imaging). Alternatively, images
were acquired by using appropriate filters of an upright confocal
microscope with attached Zeiss 5 Fluar0.25 and 10 Fluar0.50
lenses controlled by least squares means analysis.
FACS. Skin shave biopsies were obtained from two psoriasis
patients, and dermal cells allowed to emigrate in culture accord-
ing to a published protocol (18). Shave biopsies are small
superficial (split thickness) skin biopsies that give the largest
surface area for efficient emigration of DCs. Briefly, the skin was
cultured in dispase overnight, epidermis and dermis were sep-
arated, then dermis was cultured for 3 days, and the dermal
supernatant was treated with collagenase for 1 h. FACS was
performed with antibodies listed above, as described (19). A
provisional DC gate (R1) was selected based on large cell size
(FSC) and high side scatter (SCC) (see Fig. 2E) (20), and cells
in this gate were further selected for CD11c expression (R2).
Analysis of iNOS Gene Expression. DCs were prepared and analyzed
by quantitative PCR as described (6, 21). Monocytes or T cells
were isolated by negative selection (Dynal, Oslo), and activated
with CD3CD28 beads (Dynal). HaCaT cells were grown in
Dulbecco’s modified eagle medium (R & D Systems).
Statistical Analysis. Significance was defined as P  0.05 using a
Student’s t test. U scores and correlation coefficients were
computed based on a recently published technique to analyze
multivariate data (22).
Results
INOS and TNF Double-Positive CD11c Cells Are Greatly Increased in
Psoriasis Lesions. Expression of iNOS mRNA is typically elevated
by 10-fold in psoriasis lesions (4–6), and iNOS has been
detected in psoriasis lesions (23). Because a product of iNOS,
nitric oxide, is a key inflammatory mediator (24), we first set out
to localize iNOS-producing cells in normal skin versus psoriasis
lesions. Normal skin contained only a small number of iNOS
cells in the dermis (Fig. 1A), but abundant iNOS cells were
noted in both the epidermis and dermis of psoriasis lesions (Fig.
1B). In parallel, CD11c cells had a similar distribution in both
normal and diseased skin (Fig. 1 C and D). The iNOS cells were
large and stellate, with numerous dendritic processes (Fig. 5A,
which is published as supporting information on the PNAS web
site). Two-color immunofluorescence verified that iNOS was
primarily localized to the CD11c cells (Fig. 1E). Moreover,
TNF was also expressed almost exclusively in these CD11c cells
(Fig. 1F), which failed to express the Langerhans cell markers,
Langerin, (CD207) (Fig. 1D) or CD1a (data not shown), or the
monocyte marker CD14 (Fig. 5B). These data indicate that the
lesions of psoriasis contain numerous CD11c cells that coex-
press two key inflammatory mediators, iNOS and TNF, but are
not typical Langerhans cells or monocytes.
CD11c Identifies a Type of Dendritic Cell. We carried out additional
two-color immunofluorescence studies to characterize the
CD11c cells. They were larger cells and all strongly HLA-DR
positive (Fig. 2A). Some of the iNOS producers also expressed
markers of maturing DCs, DC-LAMP and CD83 (Fig. 2 B and
C), and TNF cells were predominantly HLA-DR (Fig. 2D). To
confirm that CD11c was primarily marking DCs, we performed
more sensitive flow-cytometric analyses of cells from psoriasis
lesions. The large, CD11c cells could be classified mainly as
maturing DCs, because 95% were CD86, 86% were CD40,
and 63% were CD83 (Fig. 2F). Only a small percentage of
CD11c cells were CD14 (12%), and these cells were HLA-
DRmid-low and probably best classified as monocytes. In contrast,
the CD3 cells in the lesions were primarily found in the small
cell fraction (R3), and these cells failed to express CD11c and
CD83 (Fig. 2G). Because DCs mature when emigrating from
Fig. 1. iNOS and TNF double-positive CD11c cells are greatly increased in
psoriasis lesions. Single- and double-label immunofluorescence are shown.
(Scale bar, 200 m.) (Insets) Single color staining controls. (A) iNOS cells in the
dermis of normal skin. (B) iNOS cells in the epidermis and dermis of psoriasis
skin. (C) CD11c cells in the dermis of normal skin. (D) CD11c cells in the
epidermis and dermis of psoriasis skin. No overlap with Langerin positive cells
in the epidermis in C and D. (E and F) There is nearly complete overlap between
CD11c and iNOS, and CD11c and TNF.
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skin in vitro, the FACS experiments are likely to indicate that a
high fraction of mature CD11c DCs are in the emigrating
population. Ongoing functional studies indicate that DCs emi-
grating from the dermis of psoriatic skin are strongly stimulatory
for proliferative responses in autologous blood T cells, a func-
tional property of DCs (25).
CD11c DCs Are the Major Type of Leukocyte in Psoriatic Skin.
Different types of leukocytes were then quantified by immuno-
histochemical staining, including the mean number of cellslow
power field expressing CD1a, CD11c, CD83, CD3, and CD8. We
compared normal human skin and psoriatic lesions before and
during efalizumab therapy (anti-CD11a) (Fig. 3) (5). Perhaps the
most surprising alterations in the leukocytes of psoriatic skin
lesions were the CD11c and CD83 DCs (Fig. 3 B and C).
Normal human skin or uninvolved psoriatic skin contained
similar numbers of CD11c DCs (83 and 91 cells per field,
respectively), which were exclusively localized in the dermis. In
contrast in psoriasis, there was a large increase in CD11c cells
(411 cells per field, P  1010 compared to normal skin), and
nearly half (44%) of these CD11c cells were found in the
epidermis, mainly in the lower portions and along the dermo-
epidermal junction. CD83 DCs were infrequent in normal skin
(zero to five CD83 cells per field in normal skin), but increased
to 108 CD83 DCs in active psoriasis lesions (P  105). The
overall number of CD11c cells in psoriatic skin actually ex-
ceeded the number of CD3 T cells.
CD11c DCs Are Significantly Decreased After Efalizumab (Anti-
CD11a) Treatment. Efalizumab treatment had a major impact on
skin infiltration by CD11c and CD83 DC populations. Over-
all, a 41% mean reduction in CD11c cells was measured in
patients treated with efalizumab (P  106), whereas placebo
treatment produced no significant reduction. The reductions
observed in K16 (high responder) patients was even greater,
averaging 68% for CD11c DCs, and 89% when the final number
of DCs was corrected for numbers present in nonlesional skin.
CD83 DCs were impacted even more by efalizumab treatment,
as a 90% reduction in mature DCs was observed in high
responders, with a 98% reduction when corrected by nonlesional
skin cell counts. There was a mean of 49 CD1a (Langerhans)
cells per field in normal skin, 183 lesional CD1a cells per field,
and no significant reduction in number of CD1a cells after
efalizumab treatment. These cells were evenly distributed
throughout the epidermis of normal and uninvolved skin, often
concentrated in the upper spinous layer in lesional psoriatic
Fig. 2. CD11c identifies a type of DC. (A–D) Double-label immunofluorescence. (Insets) Single-color staining controls. (A) CD11c cells are all HLA-DR. (B and
C) Some iNOS cells coproduce DC-LAMP and CD83. DC-LAMP and iNOS cells are mature dermal DCs. (D) TNF cells are predominantly HLA-DR. (E–G) FACS
of dermal emigrants from a psoriatic patient. (E) R1, cells gated based on large cell size (FSC) and high side scatter (SCC); R2, CD11c-positive cells. (F) HLA-DR versus
IgG1, CD86, CD40, CD83 and CD14 expression (R1R2). Percent double-positive cells is shown in the upper right quadrant. (G) A lymphocyte gate (R3) indicates
CD3-positive cells that have low CD11c and CD83 staining.









epidermis, and restored to normal with therapy. Highly signif-
icant decreases in CD3 and CD8 cells were observed in
efalizumab-treated patients (Fig. 3 D and E). Total CD3 cells
declined by 47% in the patients who received efalizumab (P 
106), and by 70% in K16 (high responders) (P  104). These
results indicate that CD11c cells, and not just T cells, are a
major responsive element in successful CD11a-based therapy of
psoriasis.
Changes in Number of CD11c and CD83 Cells, as Well as iNOS mRNA
Expression, Correlate Highly with Disease Improvement. We used
efalizumab as a disease-modulating agent in these studies because
it is a leukocyte-specific antibody, and both DCs and T cells express
LFA-1. A recently developed statistical approach was used to
compare disease improvement in individual patients to changes in
specific leukocyte subsets (DCs and T cells) (22). The amount of
psoriasis disease activity at the end of treatment was quantified as
a ‘‘response score’’ (Fig. 4), a composite U score derived from
measurement of epidermal thickness and K16 expression (positive
or negative) on day 56. As shown in Fig. 4A, disease improvement
(response score) could be related to changes in T cells or DCs.
However, the CD11c population showed the highest correlation
with the response score (r  0.62), whereas the correlation with T
cell changes (CD3) was relatively poor (r  0.32). Changes in
CD83 DCs were also better correlated with response (r  0.52)
than T cells. We also examined the degree to which disease
improvement during efalizumab treatment was related to altered
expression of iNOS mRNA in skin lesions. As shown in Fig. 4B,
response score was highly related to reduction in iNOS mRNA in
individual patients (r  0.83).
Therefore, we confirmed that myeloid (ex vivo peripheral blood
monocyte-derived) DCs can synthesize high levels of iNOS mRNA
by using real-time RT-PCR (Fig. 4C). Immature DCs were able to
express iNOS, but the highest level of iNOS was measured in
mature (CD83) DCs, which were differentiated in vitro by using a
cytokine mixture (21). In comparison, resting T cells, activated T
cells, blood monocytes, and a keratinocyte cell line (HaCaT cells)
produced very little iNOS mRNA. We then assessed whether
CD11c cells might be reduced before clinical improvement. As
shown in Fig. 4D, during the first 2 weeks of efalizumab treatment,
there was a 50% reduction in lesional dermal CD11c cells (P 
0.006), but only a 14% reduction in epidermal thickness (an
indicator of clinical response). The early kinetics of reduction in
CD11c cells show that these cells are decreased before thinning of
the epidermis and clinical improvement occurs.
Fig. 3. CD11c DCs are significantly decreased after efalizumab (anti-CD11a) treatment. Histomicrographs and cell counts of skin biopsies from a normal control
and a treatment group patient (responder, K16 negative), on days 0 and 56. (Scale bar, 200 m.) Mean number of total cells per low power field (10) for CD1a
(A), CD11c (B), CD83 (C), CD3 (D), and CD8 (E) (SD) in normal skin (N, black), nonlesional psoriasis skin (NL, gray), and lesional skin of patients in placebo (P),
treatment (T; all patients), K16 (non- and partial responders), and K16 (high responders) groups on days 0 (filled squares) and 56 (open squares). P values are
shown for the indicated comparison.
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Discussion
Two important mediators of inflammation, iNOS and TNF, are
known to participate in the lesions of psoriasis (23, 26), and TNF
blockade is an emerging therapy for this disease (15, 16). We now
find that the iNOS enzyme and the TNF cytokine are abundant in
a CD11c cell in lesional dermis and epidermis. These CD11c cells
are the principal reservoir for these two mediators of inflammation
and actually outnumber T cells in psoriatic lesions.
Our tissue and FACS staining data suggest that the abundant
CD11c iNOS- and TNF-producing cells in psoriasis are DCs, and
similar to the Tip-DCs seen in mice (12–14), except that expression
of CD11b is lacking on human cells (unpublished data). Murine
Tip-DCs were defined as splenic CD11c, CD11b, MHC-II,
CD40, and CD86 cells producing iNOS and TNF. Tip-DCs
appeared to originate from circulating cells expressing CCR2
(receptor for monocyte chemotactic protein-1). They were largely
absent in normal spleens, but accumulated in response to Listeria
infection. Mice unable to recruit splenic CCR2 cells were severely
compromised in their capacity to fight Listeria infection. The
differentiation of Tip-DCs required MyD88, a central regulatory
molecule in myeloid development activated by Toll-like receptors
that is responsible for the induction of a variety of proinflammatory
cytokines (27). Tip-DCs may be derived from monocytes, because
cultured monocyte-derived DCs express iNOS (Fig. 4C) and TNF
(unpublished data).
Previously, epidermal DCs in inflammatory skin lesions (atopic
dermatitis and psoriasis) have been classified as Langerhans cells,
inflammatory dendritic epidermal cells (IDECs), and plasmacytoid
DCs, by FACS techniques (28–30). Tip-DCs might contain the
IDEC population because both express the integrin CD11c (unlike
Langerhans cells). However, IDECs express CD1a, suggesting that
they might be a subset of activated Langerhans cells, and we were
unable to detect CD1a or LangerinCD207 expression on epider-
mal CD11c DCs. In previous work, dermal DCs in psoriasis were
identified by expression of factor XIIIa (31). We are finding an
increase in XIIIa cells in psoriasis lesions, but these cells are
confined to the dermis, even in active psoriasis lesions, and are
distinct from the Tip-DCs.
Efalizumab clearly blocks trafficking of LFA-1 T cells into
psoriasis skin lesions (19). The observed DC reduction with
efalizumab therapy may be due to either a direct effect on DCs
(which express CD11a; ref. 32) or a direct effect on T cells,
impacting on the DC–T cell relationship. We suspect that the
DCs are a principal target because of our observation that the
decrease in CD11c DC numbers during therapy is faster than
the reduction in epidermal thickness. Likewise, both T cells and
CD11c DCs are decreased in psoriasis lesions treated with
other immunosuppressive therapies such as CTLA4Ig or alefa-
cept (4, 6). Further proof that TNF- and iNOS-producing DCs
could be direct inflammatory effector cells in autoimmune
disease awaits the development of more DC-specific antagonists
that can be used in clinical studies.
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